The Journal of Korean Medicine Ophthalmology and Otolaryngology and Dermatology (한방안이비인후피부과학회지)

The Society of Korean Medicine Ophthalmology, Otolaryngology & Dermatology (대한한방안이비인후피부과학회)
권호 표지
DOI QR코드

DOI QR Code

Retrospective Study about the Effectiveness of Korean Medical Treatment on 101 Psoriasis Patients for 6 months

건선 환자 101명의 6개월간의 한의학적 치료효과에 대한 후향적 연구

  • Received : 2017.10.06
  • Accepted : 2017.11.10
  • Published : 2017.11.25
Download PDF
⟨ Previous Next ⟩

Abstract

Objectives : The purpose of this study is to report the effectiveness of Korean Medicine Treatment on 101 psoriasis patients for 6 months. Methods : Psoriasis Area and Severity Index(PASI) is used for measuring the degree of psoriasis with photos of total 101 psoriasis patients who have visited Korean medical clinic from October 11, 2013 to August 31, 2017. And we analyzed the PASI score according to gender, age, period of treatment, being used steroid or not. Results : 1. The ratio of male to female was 44.55 : 55.45. The mean age of patients was 34.65 years old(All patients were constituted with 9.9% of 10~19 year-old group, 31.7% of 20~29 year-old group, 26.7% of 30~39 year-old group, 12.9% of 40~49 year-old group, 15.8% of 50~59 year-old group and 3.0% of 60~69 year-old group). 2. PASI score was significantly higher in men than in women before treatment, but there was no significant difference of PASI score improvement after 2, 4 and 6 months treatment in both men and women. 3. PASI score improvement according to age after 2, 4 and 6 months treatment was no significant difference. 5. In initial visit, the steroid group patients were 61 and non-steroid group patients were 40. PASI score in initial visit between steroid group and non-steroid group was no significant difference. And PASI score after 2, 4 and 6 months treatment was no significant difference. Conclusions : PASI score was significantly decreased after 2, 4 and 6 months treatment compared with before treatment. PASI score improvement was significantly increased in proportion to the period of treatment.

Keywords

References

  1. Textbook Compilation Committee of Korean dermatological association. Dermatology. 6th ed. Seoul:Yeomoongak. 2014:299-314.
  2. Clarke P. Psoriasis. Aust Fam Physician. 2011;40(7):468-73.
  3. Shanu KK, Andrea BT, Paul CC, Joel MG. The risk of depression, anxiety, and suicidality in patients with psoriasis. Arch Dermatol. 2010;146(8):891-5. https://doi.org/10.1001/archdermatol.2010.186
  4. Nancy W, Sarah M. Psoriasis. Am Fam Physician. 2013;87(9):626-33.
  5. Kim NK, Hwang CY, Lim GS. The oriental and occidental bibliographic study of Psoriasis. J Korean Med Ophthalmol Otolaryngol Dermatol. 1999;12(1):154-78.
  6. Youn SW. The Assessment of Psoriasis Severity: PASI, BSA, DLQI. Journal of the Korean Society for Psoriasis. 2013;10(1):11-4.
  7. Rapp SR, Feldman SR, Exum ML, Fleischer AB Jr, Reboussin DM. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol. 1999;41:401-7. https://doi.org/10.1016/S0190-9622(99)70112-X
  8. Wahl A. The impact of psoriasis on psychosocial life domains;A review. Scand J Caring Sci. 1997;11:243-9. https://doi.org/10.1111/j.1471-6712.1997.tb00463.x
  9. Kurd SK, Troxel AB, Crits-Christoph P, Gelfand JM. The risk of depression, anxiety, and suicidality in patients with psoriasis: a population-based cohort study. Arch Dermatol. 2010;146:89-95.
  10. Choi JH. Pruritus in Psoriasis. The Korean Society for Skin Barrier Research. 2009;11(2).
  11. Gupta MA, Gupta AK, Kirkby S, Weiner HK, Mace TM, Schork NJ, et el. Pruritus in psoriasis. A prospective study of some psychiatric and dermatologic correlates. Arch Dermatol. 1988;124:1052-7. https://doi.org/10.1001/archderm.1988.01670070040016
  12. Yeilding N, Szapary P, Brodmerkel C, Benson J, Plotnick M, Zhou H, et al. Development of the IL-12/23 antagonist ustekinumab in psoriasis: past, present, and future perspectives. Ann NY Acad Sci. 2011;1222:30-9. https://doi.org/10.1111/j.1749-6632.2011.05963.x
  13. Kim JY, Lee WJ, Lee SJ, Kim DW, Kim TH, Jun JB, et al. An Investigation on the Use of Complementary and Alternative Medicine for Psoriasis. Korean Journal of Dermatology. 2010;48(6):494-502.
  14. Hong SH. Reviewing Research on Korean medical treatment of Psoriasis. J Korean Med Ophthalmol Otolaryngol Dermatol. 2013;26(4):26-42. https://doi.org/10.6114/jkood.2013.26.4.026
  15. Na SJ, Jo SJ, Youn JI. Clinical observation of the patients registered or the past 30 years (1982-2012) at Seoul National University Hospital Psoriasis Clinic. J Dermatol. 2013;40(9):731-5. https://doi.org/10.1111/1346-8138.12224
  16. Carlin CS, Feldman SR, Krueger JG, Menter A, Krueger GG. A 50% reduction in the Psoriasis Area and Severity Index (PASI 50) is a clinically significant endpoint in the assessment of psoriasis. J Am Acad Dermatol. 2004;50(6):859-66. https://doi.org/10.1016/j.jaad.2003.09.014
  17. Kim SY, Yun SJ, Lee JB, Kim SJ, Won YH, Lee SC. A Comparison of Efficacy and Adverse Reactions between Methotrexate and Cyclosporine A. Korean Journal of Dermatology. 2014;52(9):615-21.
  18. Lim JH, Woo YR, Kim MR, Park HJ. The Effect of Combination Treatment with Ustekinumab and Topical Agents in Korean Patients with Moderate-to-severe Psoriasis: A Retrospective Study of 30 Patients through 5 Years of Follow Up. Korean Journal of Dermatology. 2017;55(3):171-7.
  19. Yang JI, Lee KH, Kim YS, Shin MK, Yoo JH, Chang GT. A Report on Liver Function Tests of 82 Psoriasis Patients Taking Herbal Medication over 3 Months. J Korean Oriental Med. 2012;33(3):95-104.
  20. Lee BC, Cho EJ. The Safety and Efficacy of Herbal Medicine for 107 Psoriasis Patients: A Retrospective Chart Review. J Korean Med. 2016;37(1):34-40. https://doi.org/10.13048/jkm.16004
  21. Roh HJ, Bae BG, Lee JH. Recent Advances in Topical Therapy of Psoriasis. Journal of the Korean Society for Psoriasis. 2009;6(1):1-6.